For instance, since MYC overexpressing lymphomas escape rituximab-mediated cytotoxicity by downregulating CD20, patients may benefit from agents that upregulate CD20, such as the histone deacetylase (HDAC) inhibitor valproate [46], the chemotherapeutic gemcitabine [47] or PIM kinase inhibitors [21]. The gene discussed is HDAC9; the disease is lymphoma.